Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun The single
enantiomer of theracemate NSAID flurbiprofen , researched but discarded as a treatment forAlzheimer's disease .
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word tarenflurbil.
Examples
-
Testing of the amyloid hypothesis began a few years ago with two experimental anti-amyloid drugs, homotaurine and tarenflurbil.
AARP.org : 2010
-
Although there were promising results in a phase 2 trial, patients with mild Alzheimer disease who received the drug tarenflurbil as part of a phase 3 trial did not have better outcomes on measures of cognitive decline or loss of activities of daily living compared to patients who received placebo, according to a study in the December
PhysOrg.com - latest science and technology news stories 2009
-
Green, MD, MPH, of Boston University School of Medicine, shows that the drug tarenflurbil-which aims to suppress the accumulation of amyloid protein (plaque) in brain tissue-did not slow cognitive decline or loss of usual daily activities.
-
M.P.H., of the Boston University Schools of Medicine and Public Health, and colleagues conducted a large phase 3, randomized trial of tarenflurbil for patients with mild AD to determine its efficacy, safety and tolerability.
PhysOrg.com - latest science and technology news stories 2009
-
Patients were randomized to tarenflurbil, 800 mg, or placebo, administered twice a day.
PhysOrg.com - latest science and technology news stories 2009
-
Although there were promising results in a phase 2 trial, patients with mild Alzheimer disease who received the drug tarenflurbil as part of a phase 3 trial did not have better outcomes on measures of cognitive decline or loss of activities of daily living compared to patients who received placebo, according to a study in the December
PhysOrg.com - latest science and technology news stories 2009
-
The researchers found that tarenflurbil had no beneficial effect on the primary outcomes of cognition and activities of daily living after 18 months.
PhysOrg.com - latest science and technology news stories 2009
-
The researchers found that tarenflurbil had no beneficial effect on the primary outcomes of cognition and activities of daily living after 18 months.
PhysOrg.com - latest science and technology news stories 2009
-
Patients were randomized to tarenflurbil, 800 mg, or placebo, administered twice a day.
PhysOrg.com - latest science and technology news stories 2009
-
M.P.H., of the Boston University Schools of Medicine and Public Health, and colleagues conducted a large phase 3, randomized trial of tarenflurbil for patients with mild AD to determine its efficacy, safety and tolerability.
PhysOrg.com - latest science and technology news stories 2009
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.